Captor Therapeutics Cereblon-Binding Piperidine Derivatives, EP4065576A1
Summary
Captor Therapeutics S.A. has obtained publication of European Patent Application EP4065576A1 covering piperidine-2,6-dione derivatives that bind to cereblon and methods of use. The patent application was published April 15, 2026 with international classifications spanning C07D chemistry (C07D 409/12, C07D 495/04) and therapeutic uses including A61P 35/00 (oncology) and A61P 17/00 (dermatology). The application designates 35 European states including AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, and TR.
About this source
GovPing monitors EPO Patent Bulletin - Therapeutics (A61P) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 24 changes logged to date.
What changed
European Patent Application EP4065576A1 has been published by the European Patent Office, granting Captor Therapeutics S.A. patent protection for piperidine-2,6-dione derivatives that bind to cereblon protein. The invention covers methods of use for these compounds, with therapeutic applications spanning oncology (A61P 35/00), dermatology (A61P 17/00), and respiratory conditions (A61P 11/00). The application is classified under multiple C07D chemical compound categories and A61K pharmaceutical compositions.
For pharmaceutical and biotechnology companies developing cereblon-modulating therapeutics, this patent establishes priority rights that may affect freedom-to-operate assessments in the European market. Competitors should evaluate whether their research programs fall within the scope of these claims before proceeding with clinical development or commercialization efforts in designated EU member states.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
PIPERIDINE-2, 6-DIONE DERIVATIVES WHICH BIND TO CEREBLON, AND METHODS OF USE THEREOF
Publication EP4065576A1 Kind: A1 Apr 15, 2026
Applicants
Captor Therapeutics S.A.
Inventors
KACZANOWSKA, Katarzyna, COTTENS, Sylvain, PLUTA, Roman, DICKINSON, Niall, WALCZAK, Michal
IPC Classifications
C07D 409/12 20060101AFI20210604BHEP C07D 409/14 20060101ALI20210604BHEP C07D 495/04 20060101ALI20210604BHEP A61P 11/00 20060101ALI20210604BHEP A61P 17/00 20060101ALI20210604BHEP A61P 35/00 20060101ALI20210604BHEP A61K 31/4535 20060101ALI20210604BHEP C07D 405/12 20060101ALI20210604BHEP C07D 413/12 20060101ALI20210604BHEP C07D 417/12 20060101ALI20210604BHEP C07D 471/04 20060101ALI20210604BHEP C07D 487/04 20060101ALI20210604BHEP A61K 31/437 20060101ALI20210604BHEP A61K 31/4025 20060101ALI20210604BHEP A61K 31/5377 20060101ALI20210604BHEP A61K 31/4365 20060101ALI20210604BHEP A61K 31/4525 20060101ALI20210604BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Parties
Related changes
Get daily alerts for EPO Patent Bulletin - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.